Tirzepatide Dosage Guide: Reported Ranges, Reconstitution & Half-Life

Tirzepatide at a glance

What it is

A dual GIP and GLP-1 receptor agonist, approved as Mounjaro and Zepbound

Researched for

Type 2 diabetes, chronic weight management, and obstructive sleep apnea in obesity

Commonly reported range

Label starts at 2.5 mg once weekly; maintenance doses are 5, 10 or 15 mg once weekly

Route reported

Subcutaneous injection once weekly

Reported frequency

Once weekly

Reported cycle

Label increases the dose in 2.5 mg steps after at least 4 weeks at the current dose; treatment is ongoing, not cycled

Plasma half-life

Approximately 5 days (about 117 hours)

Regulatory status

FDA-approved and prescription-only. Research-market material is NOT the pharmacy product and is research use only

Reported ranges from research/community — examples, not recommendations.

What it is / mechanism

Tirzepatide is a single 39-amino-acid synthetic peptide that activates two incretin receptors rather than one: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. It is based on the native GIP sequence, with modifications and a C20 fatty-diacid chain that promotes albumin binding and extends its duration of action to support weekly dosing. Through the GLP-1 receptor it is reported to enhance glucose-dependent insulin secretion, suppress glucagon and slow gastric emptying, as with a conventional GLP-1 agonist. The added GIP-receptor activity is the distinguishing feature: published research describes GIP agonism as contributing further effects on insulin secretion, adipose-tissue handling of nutrients, and central appetite regulation. This dual action is the reported explanation for the larger average weight reduction seen with tirzepatide than with single-agonist GLP-1 therapy in head-to-head trials.

Researched effects

In clinical trials tirzepatide has been associated with marked HbA1c reduction in type 2 diabetes and with the largest average weight reductions reported for an approved incretin therapy - the SURMOUNT-1 trial reported roughly 21% mean weight reduction at 72 weeks at the highest dose in people with obesity, and SURPASS-2 reported greater HbA1c and weight reduction than semaglutide 1 mg in a head-to-head comparison. It has also been reported to reduce apnea-hypopnea events in obstructive sleep apnea with obesity. These are reported trial findings in supervised populations, not guaranteed outcomes; individual results varied and weight regain after discontinuation has been reported. Nothing here is a promise of efficacy or a personal recommendation.

Dosage — reported ranges (overview)

The figures below describe the approved label and published trials, provided as educational context rather than as a recommendation. The label starts at 2.5 mg once weekly for 4 weeks - a starting dose intended for tolerance, not for treatment effect - then increases in 2.5 mg increments after at least 4 weeks at the current dose. Recommended maintenance doses are 5 mg, 10 mg or 15 mg once weekly, with the choice guided by response and tolerability. Reaching the highest dose takes roughly 20 weeks under this schedule. The deliberate pace exists to limit gastrointestinal side effects, which are dose-related. This is a prescription medicine whose dose is selected and monitored by a clinician for an individual - the schedule above is what the label specifies, not what any particular person should take.

A printable protocol sheet with a reconstitution reference and an injection log comes with All-Access Lifetime.

Reconstitution — bac-water math

Research-market tirzepatide is supplied lyophilized, so reconstitution is a concentration calculation. Add bacteriostatic water to the vial and the concentration is the vial's total mg divided by the water volume in mL. On a U-100 insulin syringe, 100 units equals 1 mL, so units to draw = dose (mg) / concentration (mg/mL) x 100. Worked example: a 30 mg vial reconstituted with 3 mL of bacteriostatic water gives 10 mg/mL; a 5 mg example is then 5 / 10 = 0.5 mL, which is 50 units on a U-100 syringe. Note that tirzepatide research vials are commonly larger than semaglutide vials, so the same water volume yields a very different concentration - always recompute rather than reusing a figure from another compound. This is concentration math only, not a personal dose. Add water slowly down the vial wall and swirl gently rather than shaking.

This is concentration math, not a dose recommendation.

Injection / administration basics

The approved label specifies subcutaneous injection once weekly into the abdomen, thigh or upper arm, rotating the site, on the same day each week, with or without food. Approved products are supplied in single-dose pens or vials rather than as a powder requiring reconstitution. General handling concepts - sterile technique, site rotation, consistent weekly timing - are covered here as general information; the detailed workflow comes with All-Access Lifetime, which includes the printable protocol sheet and injection log for every compound. This is general educational information, not a personal administration protocol; tirzepatide is a prescription medicine and a qualified professional should direct any actual use.

Half-life & frequency rationale

Tirzepatide has a plasma half-life of approximately 5 days (about 117 hours), supporting once-weekly dosing. Steady state is reached after roughly 4 weeks of consistent weekly administration, which aligns with the label's requirement to stay at a dose for at least 4 weeks before increasing - each step is assessed near steady state. The extended half-life means the drug persists for weeks after the last dose.

Stacking — overview

Tirzepatide is itself a dual agonist, so it already combines two incretin mechanisms in one molecule - a point often missed in stacking discussion. Community discussion describes pairing it with amylin analogs such as cagrilintide, or with compounds intended to preserve lean mass during rapid weight loss, but neither is supported by approval-grade evidence. Combining a prescription incretin therapy with other agents is a clinical decision with real interaction risk, not a lifestyle choice; these reflect reported pairings, not recommendations.

For how combinations are grouped by research context, the named blends, and why a pre-mixed blend vial cannot be calculated from its total milligrams, see the peptide stacks guide.

Storage & handling

• Approved pens and vials are stored refrigerated at 2-8 C and protected from light; consult the product label for permitted room-temperature excursions, which are time-limited.
• Research-market lyophilized vials are typically stored refrigerated and protected from light; after reconstitution keep refrigerated at about 2-8 C, use within a few weeks, do not freeze and avoid shaking.

Evidence File

The Tirzepatide Evidence File: 292 Registry Records, One Undisclosed Dose, and a Superiority Test That Failed

Tirzepatide has one of the largest trial programmes in metabolic medicine, which makes an evidence file an audit rather than a search. This module reads the ClinicalTrials.gov record under all four names the compound is registered under, separates the trials that reported from the trials that quietly did not, and traces the figures that circulate in marketing copy back to the specific analysis that produced each one. It records the terminated, withdrawn and no-longer-updated studies in their sponsors' own words, reads the registry entries where the number everyone assumes exists is simply not written down, and shows one trial where the registry's posted result and the published paper's result for the same endpoint are not the same number. Every identifier here was fetched from a primary API on the verification date.

• 292 tirzepatide registry records swept, plus 79 under the code LY3298176
• SURPASS-CVOT superiority P=0.09, with the interval reaching 1.01
• 1 terminated, 4 withdrawn and 4 no-longer-updated records read verbatim
• 4 combination or comparison trials checked, none with a posted result

Sourcing File

The Tirzepatide Sourcing File: Two Exact Masses, One Missing Percentage, and a Certificate Read Line by Line

Tirzepatide is unusual among research-market peptides in having an FDA-approved twin, which means its true formula, mass and composition are published by a regulator rather than inferred. That turns a sourcing file into something a certificate can actually be measured against. This module assembles the reference values from three independent authorities, shows why one of the two exact masses in the public chemical record is not the one a mass spectrometer reports first, works the concentration arithmetic that a single missing line on a certificate quietly invalidates, and reads an illustrative certificate one row at a time to show what each line does and does not establish.

• Neutral monoisotopic 4810.5249 Da, protonated 4811.5321 Da, average 4813.53 Da
• Semaglutide sits 699.41 Da lighter and no purity figure can see it
• A stated 88% net peptide content turns a 5.00 mg draw into 4.40 mg
• 48% of 33 surveyed compounded products carried a second added ingredient

Benefit & Outcome Review

The Tirzepatide Benefit and Outcome Review: Ten Claims Graded Against What Was Actually Measured

A compound with this much evidence behind it presents an unusual problem: almost every claim made for it has a real trial somewhere in its vicinity, which makes the vague claims harder to catch rather than easier. This review takes the statements that circulate most often, finds the specific analysis each one rests on, and grades it against what that analysis measured, in whom, for how long, and against what comparator. Several of the most repeated claims turn out to be contradicted by the sponsor's own data rather than merely unproven, and those are given the most space.

• 10 claims graded against the analysis each one actually rests on
• 25% of the weight lost was lean mass, the same fraction as on placebo
• Randomized withdrawal produced a mean 14.0% regain over 52 weeks
• 43% of the top-dose group did not reach a 20% weight reduction

Guide FAQ

Quick answers about guide scope, access, and educational use context.